The primary results of an intergroup phase III randomized controlled trial comparing ramucirumab plus irinotecan with irinotecan in the third or later line treatment beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG Trial).

S. Kadowaki, D. Sakai, R. Kawabata, H. Hara, H. Yasui, M. Takahashi, M. Hirao, H. Imai, K. Minashi, T. Kawakami, H. Satake, J. Matsuyama, Y. Sakamoto, K. Sawada, M. Kataoka, H. Kawakami, T. Shimokawa, N. Boku, T. Satoh

ESMO 2023, Madrid 20 – 24 Oct 2023

Warning: Trying to access array offset on false in /home/grwdev/grwdev.works/public_html/ogsg2026.grwdev.works/wp/wp-content/themes/OGSG/single.php on line 62